EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...
The European Union's pharmaceutical reforms must maintain the current patent protection baseline, says David Kolář, executive ...
Robert F. Kennedy Jr. has pledged to tackle high rates of chronic diseases such as diabetes and obesity as President-elect ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
A new study reveals that more than half of cancer drugs approved by the FDA under accelerated pathways are not authorized in ...
InflaRx (IFRX) has released an update. InflaRx has received a positive opinion from the European Medicines Agency’s CHMP for GOHIBIC, a ...
Hosted on MSN2d
EU approves life changing 'important' Alzheimer's drug which can drastically slow onsetLecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...
Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.
The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.
Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback